Thomas Murphy, MD
Allergy & Immunology · Charleston, SCNPI 1144275827
Payments from drug & device makers
Across 1,766 payments — averaging $817.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$470K
- Novartis$198K
- Regeneron$162K
- Optinose US, Inc.$122K
- Incyte Corporation$112K
- Sanofi$88K
- plus $291K from 31 others
Across 11 payments — averaging $860.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$8K
- Insmed, Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 468 | $470,015 |
| Novartis | 16 | $197,550 |
| Regeneron | 555 | $162,005 |
| Optinose US, Inc. | 111 | $122,017 |
| Incyte Corporation | 134 | $112,237 |
| Sanofi | 106 | $88,097 |
| Paratek Pharmaceuticals, Inc. | 5 | $71,889 |
| Regeneron Healthcare Solutions, Inc. | 93 | $53,957 |
| GSK | 69 | $52,216 |
| Genentech USA, Inc. | 63 | $43,618 |
| Insmed, Inc. | 3 | $38,403 |
| F. Hoffmann-la Roche AG | 13 | $12,329 |
| Amgen | 11 | $8,040 |
| Alk-abello, Inc | 16 | $3,785 |
| Genentech, Inc. | 10 | $3,414 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $297 |
| Grifols USA, LLC | 13 | $265 |
| Pharming Healthcare, Inc. | 12 | $242 |
| Sanofi-aventis U.S. LLC | 4 | $211 |
| CSL Behring | 7 | $179 |
| Stryker | 1 | $176 |
| Pfizer | 8 | $138 |
| Kaleo, Inc. | 7 | $118 |
| Astrazeneca UK Limited | 1 | $111 |
| Hikma Pharmaceuticals USA | 6 | $101 |
| Merck | 3 | $96 |
| Biocryst US Sales Co., LLC | 3 | $90 |
| Neurent Medical Limited | 1 | $90 |
| Ionis Pharmaceuticals, Inc. | 3 | $72 |
| Aerin Medical Inc. | 1 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Blueprint Medicines Corporation | 2 | $42 |
| Intersect ENT, Inc. | 1 | $42 |
| Phadia US Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| The North Carolina Mutual Wholesale Drug Company Inc | 1 | $0 |
How this compares
$1,443,126 in reported general payments places this provider in the 95th percentile of 46 allergy & immunology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Charleston
- Andrew DavidsonCharleston$63K
- Carolyn WordCharleston$10K
- Jeffrey DietrichCharleston$8K
- Lindsey SteadmanCharleston$6K
- Brian DantzlerCharleston$2K
- Thomas HarperCharleston$1K
- John RameyNorth Charleston$1.5M
- Douglas JohnstonGreenville$1.3M
- Patricia GerberNorth Charleston$970K
- Ned RuppNorth Charleston$861K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.